AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03427983 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regular Injection
Description: Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
Study NCT01756144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2
Study NCT01756144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Study NCT02602483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT02602483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT02602483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Study NCT02602483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Study NCT02602483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Study NCT02602483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Study NCT02602483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03708705 — intervention group
Intervention type: OTHER
Intervention: Risk model of tumor relapse
Description: High risk factor model of tumor relapse after liver transplantation
Study NCT00992719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
Study NCT00992719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated H1N1 Vaccine
Description: H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
Study NCT04662437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood was collected for biochemistry testing
Description: From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
Study NCT03385577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer
Description: 'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
Study NCT01183442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: orally administered 2800 IU of vitamin D or placebo daily
Study NCT01153789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthoptic rehabilitation
Description: Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
Study NCT01153789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Orthoptic diagnostic
Description: postural, oculomotor and orthoptics tests
Study NCT01183442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: orally administered 2800 IU of vitamin D or placebo daily
Study NCT02505893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human pancreatic islet
Description: One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
Study NCT02505893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
Study NCT02505893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Description: Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
Study NCT02505893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
Study NCT01383239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Postoperative Therapy
Description: All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
Study NCT01383239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Physical Therapy
Description: All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
Study NCT04157218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)
Description: The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
Study NCT04157218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threads used in this study are absorbable Aptos
Description: The threads will be inserted to the cheeks
Study NCT04197479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablets
Study NCT04197479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet
Study NCT02609802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
Study NCT02609802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
Study NCT00884416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib dose escalation
Description: Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
Study NCT04148118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 50 µg - sprayer - IN
Description: 20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart.
Study NCT04148118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 50 µg - pipette - IN
Description: 20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart.
Study NCT04148118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 100 µg - sprayer - IN
Description: 20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart
Study NCT04148118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 100 µg - pipette - IN
Description: 20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart.
Study NCT04148118 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo) - sprayer - IN
Description: Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart.
Study NCT04148118 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo) - pipette - IN
Description: Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart.
Study NCT04148118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax (positive control) - SC
Description: BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart.
Study NCT01648036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
Study NCT01648036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Dose 5000 IU, subcutaneous, daily
Study NCT00302523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: FK506,0.1mg/kg/d
Study NCT02187289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night-time compression bandages
Description: Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
Study NCT02187289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Sleeve, daytime wear
Study NCT00671125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
Study NCT00671125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
Study NCT00671125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
Study NCT04424914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scintigraphy
Description: scintigraphy
Study NCT00671099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Polyunsaturated Fatty Acid
Description: A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
Study NCT00671099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00869583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents \[METS\]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
Study NCT03047564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated Total Knee Arthroplasty
Description: Implantation of a coated Total Knee Arthroplasty
Study NCT03047564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Knee Arthroplasty
Description: Implantation of a Standard Total Knee Arthroplasty
Study NCT04527978 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study NCT04527978 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study NCT02924805 — intervention group
Intervention type: OTHER
Intervention: Telemedical care
Description: Telemedically guided care based on a standard operating procedure
Study NCT01038752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin Drug:Docetaxel Drug: Carboplatin
Description: Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
Study NCT01038752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug: Docetaxel Drug: Carboplatin
Description: Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
Study NCT00714155 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, Physical Examination
Description: Questionnaires, Physical Examination
Study NCT01267422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2-ND4
Description: injection
Study NCT01608191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT follow up
Description: 11 weeks programme conducted via internet. CBT with focus on weight stability.
Study NCT02362152 — intervention group
Intervention type: DRUG
Intervention: Ingenol mebutate
Description: Topical field treatment as prescribed by dermatologist
Study NCT02362152 — intervention group
Intervention type: DRUG
Intervention: 5-fluorouracil
Description: Topical field treatment as prescribed by dermatologist
Study NCT02362152 — intervention group
Intervention type: DRUG
Intervention: Imiquimod
Description: Topical field treatment as prescribed by dermatologist
Study NCT02362152 — intervention group
Intervention type: DRUG
Intervention: Diclofenac
Description: Topical field treatment as prescribed by dermatologist
Study NCT03358381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the gap balance type of total knee arthroplasty
Description: A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.
Study NCT03358381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the measured resection type of total knee arthroplasty
Description: A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
Study NCT02700880 — intervention group
Intervention type: DEVICE
Intervention: LifeVest
Description: LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
Study NCT01317524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Homogenized milk
Description: 900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
Study NCT01317524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unhomogenized milk
Description: 900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
Study NCT01317524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skimmed Milk
Description: 900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
Study NCT00413933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive Multidisciplinary Intervention
Description: Comprehensive Multidisciplinary Intervention
Study NCT03470623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioabsorbable screws
Description: Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw
Study NCT03470623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: steel screws
Description: Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
Study NCT03647072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP only
Study NCT03647072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP Plus Lanzoprazole
Description: CHOP plus Lanzoprazole 60 mg
Study NCT03647072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP Plus Famotidine
Description: CHOP Plus Famotidine 40 mg
Study NCT01903993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants received starting dose of 75 mg/m\^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
Study NCT02187289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve, daytime wear
Study NCT02187289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night-time Compression custom-made garment
Description: Standard Care plus night-time compression by a custom-made night time compression system garment.
Study NCT02033473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: An apelin clamp in which an apelin infusion will be administered
Study NCT02033473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apelin
Description: An apelin clamp in which an apelin infusion will be administered
Study NCT02033473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A clamp reference during which a placebo solution (saline solution) will be administered
Study NCT02033473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A clamp reference during which a placebo solution (saline solution) will be administered
Study NCT00677768 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Sample collection
Study NCT01200498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
Study NCT05815706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDELA Supplemental nursing system
Description: The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
Study NCT02444728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg BID for 12 months
Study NCT02444728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1000mg intravenous infusion every month for 6 months
Study NCT02444728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
Study NCT02444728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
Study NCT04122482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Course
Description: The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
Study NCT03040830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 100 IM/day
Description: Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
Study NCT03040830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 100 IM/day
Description: Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm